CelluTarget · Multifocal Motor Neuropathy · Clinical Trials
Phase 3
Completed
NCT01827072

IVIG (Gammagard Liquid 10%)

Sponsored by Takeda Pharmaceutical Company ↗
View on ClinicalTrials.gov ↗
Timeline
Study Dates
Start Date
April 2013
Est. Completion
—
Enrollment Target
13 participants
Status
Completed
Study Design
Primary Endpoint
MRC sum score and hand-grip strength at week 52
Registry
ClinicalTrials.gov Record
Registry ID
NCT01827072
Direct Link
clinicaltrials.gov/NCT01827072 ↗
Related Treatment
Treatment Being Studied
IVIG (Gammagard Liquid 10%) →